北京福元医药股份有限公司关于公司参与国家组织集采药品协议期满品种接续采购拟中选的公告

Core Viewpoint - Beijing Fuyuan Pharmaceutical Co., Ltd. has participated in the national organized procurement for expiring drug agreements and has several products expected to be selected for continued procurement, which is anticipated to positively impact the company's market share and future operating performance [1][2]. Group 1: Announcement of Selected Products - The company participated in the national organized procurement for expiring drug agreements on February 9, 2026, and has several key products expected to be selected for this procurement [1]. - The selected products include the top five in terms of revenue scale, with additional products such as Venlafaxine Hydrochloride Sustained-Release Capsules also participating [1]. - The procurement cycle for the selected products will run from the date of selection until December 31, 2028 [1]. Group 2: Impact of Selection on the Company - The expected selection of products is projected to stabilize the company's existing market share despite a decrease in sales prices [2]. - The company aims to leverage its brand influence and reliable supply capabilities to further increase its market share, which is expected to have a positive impact on future operating performance [2]. - The implementation of the procurement results is anticipated to begin by the end of March 2026, with provincial medical institutions signing procurement contracts based on the selection results [2].